银杏叶胶囊联合单硝酸异山梨酯治疗冠状动脉粥样硬化性心脏病心绞痛的疗效及其对内皮功能的影响
|
摘要
目的探讨银杏叶胶囊联合单硝酸异山梨酯治疗冠状动脉粥样硬化性心脏病(简称冠心病)心绞痛的疗效及对患者内皮功能的影响。方法选择医院2017年1月至2018年1月收治的冠心病心绞痛患者215例,随机分为对照组(107例)和治疗组(108例)。两组患者均给予单硝酸异山梨酯治疗,治疗组患者联用银杏叶胶囊治疗,两组均连续治疗3个月。结果治疗组的总有效率为89.81%,高于对照组的70.09%(χ~2=13.065,P=0.000);治疗后,两组患者的左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、内皮素(ET)、C反应蛋白(CRP)、白细胞介素6(IL-6)及肿瘤坏死因子-α(TNF-α)水平均明显低于治疗前(P <0.05),左心室射血分数(LVEF)及血清一氧化氮(NO)、一氧化氮合酶(NOS)水平均明显高于治疗前,且治疗组患者的LVESV,LVEDV,LVEF及血清NO,NOS,ET,CRP,IL-6,TNF-α水平的变化幅度均明显优于对照组(P <0.05);两组不良反应发生率相当(4.63%比3.74%,χ~2=0.106,P=0.744)。结论银杏叶胶囊联合单硝酸异山梨酯治疗冠心病心绞痛的疗效显著,可明显改善心功能和血管内皮功能,减轻炎性反应,且安全性较好。
Objective To investigate the clinical effect of Yinxingye Capsules combined with isosorbide mononitrate in the treatment of angina pectoris of coronary heart disease and its effect on endothelial function.Methods Totally 215 patients with angina pectoris of coronary heart disease admitted to our hospital from January 2017 to January 2018 were selected and randomly divided into the control group(107 cases) and the treatment group(108 cases).The patients in the two groups were treated with isosorbide mononitrate,on this basis, the patients in the treatment group were treated with Yinxingye Capsules.The two groups were treated continuously for 3 months.Results The total effective rate of the treatment group was 89.81%,which was higher than 70.09% of the control group(χ~2=13.065, P = 0.000).After treatment, the levels of left ventricular end-systolic volume(LVESV), left ventricular end-diastolic volume(LVEDV), endothelin(ET), C-reactive protein(CRP), interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) in the two groups were significantly lower than those before treatment(P < 0.05),while the levels of left ventricular ejection fraction(LVEF),serum nitric oxide(NO) and nitric oxide synthase(NOS) in the two groups were significantly higher than those before treatment,and the change of LVESV,LVEDV,LVEF and serum NO,NOS,ET,CRP,IL-6,TNF-α levels in the treatment group was significantly better than that in the control group(P < 0.05).The incidence rate of adverse reactions in the two groups was similar(4.63% vs.3.74%, χ2= 0.106,P = 0.744).Conclusion Yinxingye Capsules combined with isosorbide mononitrate are effective in the treatment of angina pectoris of coronary heart disease, which can significantly improve cardiac function and vascular endothelial function,reduce inflammatory reaction,and have better safety.
Objective To investigate the clinical effect of Yinxingye Capsules combined with isosorbide mononitrate in the treatment of angina pectoris of coronary heart disease and its effect on endothelial function.Methods Totally 215 patients with angina pectoris of coronary heart disease admitted to our hospital from January 2017 to January 2018 were selected and randomly divided into the control group(107 cases) and the treatment group(108 cases).The patients in the two groups were treated with isosorbide mononitrate,on this basis, the patients in the treatment group were treated with Yinxingye Capsules.The two groups were treated continuously for 3 months.Results The total effective rate of the treatment group was 89.81%,which was higher than 70.09% of the control group(χ~2=13.065, P = 0.000).After treatment, the levels of left ventricular end-systolic volume(LVESV), left ventricular end-diastolic volume(LVEDV), endothelin(ET), C-reactive protein(CRP), interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) in the two groups were significantly lower than those before treatment(P < 0.05),while the levels of left ventricular ejection fraction(LVEF),serum nitric oxide(NO) and nitric oxide synthase(NOS) in the two groups were significantly higher than those before treatment,and the change of LVESV,LVEDV,LVEF and serum NO,NOS,ET,CRP,IL-6,TNF-α levels in the treatment group was significantly better than that in the control group(P < 0.05).The incidence rate of adverse reactions in the two groups was similar(4.63% vs.3.74%, χ2= 0.106,P = 0.744).Conclusion Yinxingye Capsules combined with isosorbide mononitrate are effective in the treatment of angina pectoris of coronary heart disease, which can significantly improve cardiac function and vascular endothelial function,reduce inflammatory reaction,and have better safety.
引文
[1]田华,王素琴,李雪梅.冠心病的研究进展[J].世界最新医学信息文摘,2016,16(76):52-53.
[2]孙勋,孙继雷.冠心病心绞痛心血管内科治疗的临床分析[J].中国卫生标准管理,2018,9(7):67-69.
[3]尹兰英,侯爱洁.冠心病心绞痛的中西医结合治疗进展[J].中国民族民间医药,2017,26(21):40-43.
[4]路文科,牛红霞,齐志士.单硝酸异山梨酯治疗冠心病心绞痛的疗效观察[J].实用心脑肺血管病杂志,2011,19(11):1915-1916.
[5]宋湘敏.银杏叶胶囊治疗冠心病心绞痛30例[J].浙江中医杂志,2013,48(6):467.
[6]中华医学会心血管病学会分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[7]陈可冀,廖家帧,肖镇祥,等.心脑血管疾病研究[M].北京:中国医药科技出版社,2002:108-109.
[8]李娜娜,杨关林.从脾论治冠心病心绞痛理论及临床研究进展[J].湖南中医杂志,2017,33(3):157-160.
[9]谭巨涛.银杏叶胶囊治疗冠心病心绞痛30例疗效观察[J].山西医药杂志(下半月),2011,40(9):933-934.
[10]金萍.银杏叶的药理功能及银杏叶胶囊临床治疗高脂血症的研究[J].首都医药,2012,19(8):50-51.
[11]王富彪,曹建东.银杏叶胶囊联合单硝酸异山梨酯治疗冠心病心绞痛的临床研究[J].现代药物与临床,2018,33(4):777-781.
[12]王强,宋小宁,余卓文,等.银杏叶胶囊与通心络胶囊治疗老年冠心病心绞痛疗效比较[J].遵义医学院学报,2004,27(6):549-550.
[13]李莉,周晓钢.老年冠心病患者血清NO及NOS含量的变化[J].保健医学研究与实践,2011,8(4):14-19.
[14]李兰亚.冠心病患者血浆ET-1和血清c TnⅠ、Hcy、NO水平检测的临床意义[J].淮海医药,2015,33(6):539-540.
[15]张安富,周川,杨林,等.银杏叶胶囊治疗冠心病40例临床观察[J].中国现代药物应用,2011,5(5):109-110.
[16]刘明辉,孙然,齐山,等.银杏叶注射液对冠心病患者血清CRP、TNF-α水平的影响及临床疗效分析[J].中国医药导报,2012,9(20):105-106.
[17]南娜,赵萍,张睿.银杏叶提取物对NF-κB活性抑制人视网膜色素上皮细胞炎症反应的影响[J].中国实验方剂学杂志,2017,23(18):163-167.
[2]孙勋,孙继雷.冠心病心绞痛心血管内科治疗的临床分析[J].中国卫生标准管理,2018,9(7):67-69.
[3]尹兰英,侯爱洁.冠心病心绞痛的中西医结合治疗进展[J].中国民族民间医药,2017,26(21):40-43.
[4]路文科,牛红霞,齐志士.单硝酸异山梨酯治疗冠心病心绞痛的疗效观察[J].实用心脑肺血管病杂志,2011,19(11):1915-1916.
[5]宋湘敏.银杏叶胶囊治疗冠心病心绞痛30例[J].浙江中医杂志,2013,48(6):467.
[6]中华医学会心血管病学会分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[7]陈可冀,廖家帧,肖镇祥,等.心脑血管疾病研究[M].北京:中国医药科技出版社,2002:108-109.
[8]李娜娜,杨关林.从脾论治冠心病心绞痛理论及临床研究进展[J].湖南中医杂志,2017,33(3):157-160.
[9]谭巨涛.银杏叶胶囊治疗冠心病心绞痛30例疗效观察[J].山西医药杂志(下半月),2011,40(9):933-934.
[10]金萍.银杏叶的药理功能及银杏叶胶囊临床治疗高脂血症的研究[J].首都医药,2012,19(8):50-51.
[11]王富彪,曹建东.银杏叶胶囊联合单硝酸异山梨酯治疗冠心病心绞痛的临床研究[J].现代药物与临床,2018,33(4):777-781.
[12]王强,宋小宁,余卓文,等.银杏叶胶囊与通心络胶囊治疗老年冠心病心绞痛疗效比较[J].遵义医学院学报,2004,27(6):549-550.
[13]李莉,周晓钢.老年冠心病患者血清NO及NOS含量的变化[J].保健医学研究与实践,2011,8(4):14-19.
[14]李兰亚.冠心病患者血浆ET-1和血清c TnⅠ、Hcy、NO水平检测的临床意义[J].淮海医药,2015,33(6):539-540.
[15]张安富,周川,杨林,等.银杏叶胶囊治疗冠心病40例临床观察[J].中国现代药物应用,2011,5(5):109-110.
[16]刘明辉,孙然,齐山,等.银杏叶注射液对冠心病患者血清CRP、TNF-α水平的影响及临床疗效分析[J].中国医药导报,2012,9(20):105-106.
[17]南娜,赵萍,张睿.银杏叶提取物对NF-κB活性抑制人视网膜色素上皮细胞炎症反应的影响[J].中国实验方剂学杂志,2017,23(18):163-167.